Status:
COMPLETED
Early Therapy of Pulmonary Arterial Hypertension
Lead Sponsor:
Medical University of Graz
Collaborating Sponsors:
Actelion
Conditions:
Pulmonary Hypertension
Systemic Sclerosis
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Exercise-induced increase of the pulmonary arterial pressure may be an early sign of pulmonary arterial hypertension. It has been shown that patients with normal pulmonary arterial pressure at rest bu...
Detailed Description
Bosentan is an established therapy in pulmonary arterial hypertension, which may be diagnosed when the mean pulmonary arterial pressure is \>25mmHg at rest or \>30mmHg at exercise. Bosentan has shown ...
Eligibility Criteria
Inclusion
- exercise-induced pulmonary hypertension
- systemic sclerosis
Exclusion
- relevant pulmonary obstruction or restriction
- relevant left cardiac disease
- recent changes in medical therapy
- recent major operations
- recent major cardiovascular diseases
- inability to perform exercise
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00909337
Start Date
January 1 2008
End Date
June 1 2010
Last Update
September 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Graz, Pulmonology
Graz, Austria, 8036